Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 to 64 Women only

Postpartum high blood pressure: which medicine works better after delivery

Official title: Postpartum Evaluation of Antihypertensive Cessation and Efficacy (PEACE): A Randomized Controlled Trial Comparing Oral Labetalol and Oral Extended-Release Nifedipine for Managing Postpartum Hypertension

Run by University of California, Los Angeles · NCT06915792 · Data updated 2026-11-12

This trial tests whether extended-release nifedipine works better than labetalol to control blood pressure after giving birth.

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years to 64 Years
SexWomen only
Enrollment110 (estimated)
SponsorUniversity of California, Los Angeles
Academic / other
Locations1 site (Los Angeles, California)
StatusRecruiting
StartedJune 1, 2025
Main results expectedJuly 31, 2027
Study endsOctober 31, 2027
Registry record updatedJune 5, 2026
Trial IDNCT06915792 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Postpartum adults (≥18) with hypertensive disorders of pregnancy who delivered at UCLA and require oral antihypertensive therapy postpartum.

Probably not a fit

Patients with allergies to either study medication or significant comorbidities may not benefit from this comparison.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized trial assigns 110 postpartum participants with hypertensive disorders of pregnancy to receive either labetalol or extended-release nifedipine. The goal is to see which medication better maintains blood pressure control beyond six weeks postpartum. Primary outcome is continued antihypertensive use beyond 6 weeks postpartum; secondary outcomes include readmissions, side effects, and need to switch or add another antihypertensive. Remote blood pressure monitoring is used to evaluate effectiveness. The study is conducted at UCLA with participants who delivered at the same institution.

Why it matters

Potential benefit: If successful, the better-performing medication could simplify postpartum blood pressure management and reduce readmissions.

How similar studies have gone: Previous research compares labetalol and nifedipine for postpartum hypertension, but direct head-to-head randomized data are limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion criteria:

Age ≥18 years Delivery at study institution at ≥28 weeks gestation Postpartum SBP \> 150 and/or DBP \> 100 OR 2 or more SBP \> 140 and/or DBP \> 90 within a 24-hour period Require initiation of an oral antihypertensive medication during postpartum hospital stay or within 7 days of discharge Treating obstetric team amenable to starting either study medication

Exclusion criteria:

Treated with oral antihypertensive medications prior to delivery Known allergies or contraindications to nifedipine or labetalol History of moderate persistent to severe asthma, chronic obstructive pulmonary disease, heart failure, or greater than first-degree atrioventricular heart block Unable to provide written informed consent in English

Where it's running

  • UCLA Ronald Reagan
    Los Angeles, California, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.